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Summary
Background Biologically distinct subtypes of diffuse large B-cell lymphoma can be identified using gene-expression 
analysis to determine their cell of origin, corresponding to germinal centre or activated B cell. We aimed to investigate 
whether adding bortezomib to standard therapy could improve outcomes in patients with these subtypes.
Methods In a randomised evaluation of molecular guided therapy for diffuse large B-cell lymphoma with 
bortezomib (REMoDL-B), an open-label, adaptive, randomised controlled, phase 3 superiority trial, participants 
were recruited from 107 cancer centres in the UK (n=94) and Switzerland (n=13). Eligible patients had previously 
untreated, histologically confirmed diffuse large B-cell lymphoma with sufficient diagnostic material from initial 
biopsies for gene-expression profiling and pathology review; were aged 18 years or older; had ECOG performance 
status of 2 or less; had bulky stage I or stage II–IV disease requiring full-course chemotherapy; had measurable 
disease; and had cardiac, lung, renal, and liver function sufficient to tolerate chemotherapy. Patients initially 
received one 21-day cycle of standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone 
(R-CHOP; rituximab 375 mg/m², cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², and vincristine 
1·4 mg/m² [to a maximum of 2 mg total dose] intravenously on day 1 of the cycle, and prednisolone 100 mg orally 
once daily on days 1–5). During this time, we did gene-expression profiling using whole genome cDNA-mediated 
annealing, selection, extension, and ligation assay of tissue from routine diagnostic biopsy samples to determine 
the cell-of-origin subtype of each participant (germinal centre B cell, activated B cell, or unclassified). Patients 
were then centrally randomly assigned (1:1) via a web-based system, with block randomisation stratified by 
international prognostic index score and cell-of-origin subtype, to continue R-CHOP alone (R-CHOP group; 
control), or with bortezomib (RB-CHOP group; experimental; 1·3 mg/m² intravenously or 1·6 mg/m² 
subcutaneously) on days 1 and 8 for cycles two to six. If RNA extracted from the diagnostic tissues was of 
insufficient quality or quantity, participants were given R-CHOP as per the control group. The primary endpoint 
was 30-month progression-free survival, for the germinal centre and activated B-cell population. The primary 
analysis was on the modified intention-to-treat population of activated and germinal centre B-cell population. 
Safety was assessed in all participants who were given at least one dose of study drug. We report the progression-
free survival and safety outcomes for patients in the follow-up phase after the required number of events occurred. 
This study was registered at ClinicalTrials.gov, number NCT01324596, and recruitment and treatment has 
completed for all participants, with long-term follow-up ongoing.
Findings Between June 2, 2011, and June 10, 2015, 1128 eligible patients were registered, of whom 918 (81%) were 
randomly assigned to receive treatment (n=459 to R-CHOP, n=459 to RB-CHOP), comprising 244 (26·6%) with 
activated B-cell disease, 475 (51·7%) with germinal centre B cell disease, and 199 (21·7%) with unclassified disease. 
At a median follow-up of 29·7 months (95% CI 29·0–32·0), we saw no evidence for a difference in progression-free 
survival in the combined germinal centre and activated B-cell population between R-CHOP and RB-CHOP (30-month 
progression-free survival 70·1%, 95% CI 65·0–74·7 vs 74·3%, 69·3–78·7; hazard ratio 0·86, 95% CI 0·65–1·13; 
p=0·28). The most common grade 3 or worse adverse event was haematological toxicity, reported in 178 (39·8%) of 
447 patients given R-CHOP and 187 (42·1%) of 444 given RB-CHOP. However, RB-CHOP was not associated with 
increased haematological toxicity and 398 [87·1%] of 459 participants assigned to receive RB-CHOP completed 
six cycles of treatment. Grade 3 or worse neuropathy occurred in 17 (3·8%) patients given RB-CHOP versus 
eight (1·8%) given R-CHOP. Serious adverse events occurred in 190 (42·5%) patients given R-CHOP, including 
five treatment-related deaths, and 223 (50·2%) given RB-CHOP, including four treatment-related deaths.
Interpretation This is the first large-scale study in diffuse large B-cell lymphoma to use real-time molecular 
characterisation for prospective stratification, randomisation, and subsequent analysis of biologically distinct 
subgroups of patients. The addition of bortezomib did not improve progression-free survival. 
Lancet Oncol 2019; 20: 649–62
Published Online 
April 1, 2019 
http://dx.doi.org/10.1016/
S1470-2045(18)30935-5
See Comment page 605
Cancer Research UK Centre 
(Prof A Davies PhD, 
T E Cummin MRCP, 
Prof P W M Johnson FMedSci) 
and Southampton Clinical 
Trials Unit (A Davies, 
T E Cummin, 
T Maishman PhD, J Caddy BSc, 
L Stanton MSc, 
Prof G Griffiths PhD), University 
of Southampton, 
Southampton, UK; 
Haematological Malignancy 
Diagnostic Service, Leeds 
Cancer Centre, Leeds Teaching 
Hospitals, Leeds, UK 
(S Barrans PhD, Prof R Tooze PhD, 
C Burton FRCPath); Medical 
Oncology, Cantonal Hospital 
Aarau, Switzerland 
(Prof C Mamot MD); 
Department of Medical 
Oncology, Inselspital, Bern 
University Hospital, University 
of Bern, Switzerland 
(U Novak MD); Centre for Drug 
Development, Cancer Research 
UK, London, UK 
(S Kazmi-Stokes PhD); 
Department of Haematology, 
Nottingham University 
Hospitals NHS Trust, 
Nottingham, UK 
(A McMillan FRCPath); 
Department of Haematology, 
Guy’s and St Thomas’ Hospitals 
NHS Trust, Kings Health 
Partners, London, UK 
(P Fields MD); Department of 
Haematology, East Kent 
Hospitals University 
Foundation Trust, Canterbury, 
UK (C Pocock PhD); Oxford 
Cancer and Haematology 
Centre, Churchill Hospital, 
Oxford, UK 
(G P Collins FRCPath); National 
Cancer Research Institute 
Consumer Forum, London, UK 
Articles
650 www.thelancet.com/oncology   Vol 20   May 2019
(R Stephens MA); Department 
of Pathology, University of 
Cambridge, Cambridge, UK 
(F Cucco PhD, A Clipson PhD, 
Prof M-Q Du PhD); and School 
of Molecular and Cellular 
Biology, Faculty of Biological 
Sciences (C Sha PhD, 
Prof D R Westhead DPhil) and 
Section of Experimental 
Haematology 
(Prof R Tooze, M A Care PhD), 
University of Leeds, Leeds, UK
Correspondence to: 
Professor Peter W M Johnson, 
Cancer Research UK Centre, 
University of Southampton, 
Southampton SO16 6YD, UK 
johnsonp@soton.ac.uk
Funding Janssen-Cilag, Bloodwise, and Cancer Research UK.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license. 
Introduction
The combination of rituximab, cyclophosphamide, 
doxorubicin, vincristine, and prednisolone (R-CHOP) 
has been considered standard of care for diffuse large 
B-cell lymphoma for more than 15 years.1 In trials of 
R-CHOP, 5-year progression-free survival has been 
reported to be 70–75% and overall survival 75–80%,2 
although unselected population-based studies show 
lower figures.3 Patients with lymphoma that does not 
respond to R-CHOP or that recurs have a poor prognosis, 
with only a third alive at 2 years after diagnosis.4 Various 
approaches have been attempted to improve outcomes 
for patients with diffuse large B-cell lymphoma, but none 
has so far increased overall survival. The recognised 
molecular heterogeneity of this aggressive lymphoma 
contributes to the complexity of this problem.5
Gene-expression profiling of diffuse large B-cell 
lymphoma has been used to define subgroups with 
distinct pathogenesis. Cell-of-origin classification recog-
nises those cases with a gene expression similar to that 
of peripheral blood B cells undergoing in-vitro antigen 
activation, referred to as the activated B-cell subtype, 
whereas the germinal centre B-cell subtype resembles 
B cells in the germinal centre. Retrospective analyses 
suggest that the patients with the activated B-cell subtype 
have worse outcomes, with 40% 3-year progression-free 
survival after R-CHOP compared with 75% in the 
germinal centre B-cell group.5
The subtypes have distinct genomic characteristics. 
The activated B-cell subtype shows a higher prevalence of 
mutations in genes involved in B-cell receptor signalling 
and regulators of nuclear factor (NF)-κB (MYD88, 
CD79B, TNFAIP3, CARD11, TRAF2, TRAF5, MAP3K7, 
and TNFRSF11A) than the germinal centre B-cell 
subtype. Constitutive NF-κB activation down stream of 
the B-cell receptor is a feature of the activated B-cell 
subtype of diffuse large B-cell lymphoma. Genomic, 
pharmacological, and RNA interference screens have 
shown selective oncogenic addiction of the activated 
B-cell subtype to activation of this protein complex.6 
Bortezomib is a proteasome inhibitor and can suppress 
NF-κB activity by preventing proteosomal degradation 
Research in context
Evidence before this study
We searched PubMed for publications of randomised clinical 
trials in English between Jan 1, 1998, and Dec 1, 2010, using the 
terms “diffuse large B-cell lymphoma” and “cell of origin”, and 
studies involving “diffuse-large B-cell lymphoma” and 
“bortezomib”. Using gene-expression profiling to characterise 
patients, several retrospective studies of patients treated with 
rituximab, cyclophosphamide, doxorubicin, vincristine, and 
prednisolone (R-CHOP) or CHOP-like regimens had shown that 
the activated B-cell subtype was associated with inferior 
survival compared with the germinal centre B-cell subtype. 
Bortezomib had shown restricted single-agent activity in 
diffuse large B-cell lymphoma but had been successfully 
combined with standard chemotherapy regimens in a phase 2 
study. In another phase 2 study, bortezomib in combination 
with dose-adjusted R-EPOCH (rituximab, etoposide, 
cyclophosphamide, doxorubicin, vincristine, and prednisolone) 
had resulted in longer progression-free survival in patients with 
the activated B-cell subtype than in those with the germinal 
centre B-cell subtype. Bortezomib in combination with R-CHOP 
had produced similar outcomes in non-germinal centre B-cell 
diffuse large B-cell lymphoma (ascertained by 
immunohistochemistry) compared with germinal centre B-cell 
diffuse large B-cell lymphoma in a further phase 2 study.
Added value of this study
To our knowledge, this study is the first to combine 
prospective gene-expression profiling of lymphoma with a 
targeted therapy to allow stratification and random 
assignment of patients to treatment within a phase 3 clinical 
trial. It is the first study to assess a novel agent in diffuse large 
B-cell lymphoma, prospectively powered to address subtypes 
defined by gene-expression profiling, and we have shown 
that the addition of bortezomib to R-CHOP (RB-CHOP) does 
not improve survival in the activated B-cell subgroup. 
Extensive characterisation and subgroup analyses suggest 
that cell-of-origin subtype and nuclear factor (NF)-κB 
activating mutations are not associated with improved 
outcomes with RB-CHOP, and that bortezomib does not act 
as an effective inhibitor of the NF-κB pathway in this disease. 
Exploratory analyses, however, suggest that different 
high-risk subgroups—double-expressor lymphoma and 
double-hit lymphoma—might benefit from the addition of 
bortezomib or similar agents to standard 
immunochemotherapy.
Implications of all the available evidence
The trial design provides a rational framework for future studies 
in diffuse large B-cell lymphoma, allowing prompt initiation of 
treatment while molecular characterisation is carried out. 
We confirm that R-CHOP is a good standard of care for most 
patients with diffuse large B-cell lymphoma, but raise the 
possibility that high-risk subgroups could benefit from the 
addition of a proteasome inhibitor to standard therapy, which 
could guide future research.
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of the inhibitor IκBα, thereby keeping NF-κB inactive 
and unable to translocate to the nucleus to mediate 
transcription. Preliminary clinical studies7 suggested that 
bortezomib had selective efficacy in diffuse large B-cell 
lymphoma subtypes. When combined with infusional 
chemotherapy, bortezomib appeared to have preferential 
activity in relapsed or refractory activated B-cell diffuse 
large B-cell lymphoma, with a higher response rate and 
median overall survival than that achieved with infusional 
chemotherapy alone.7
The randomised evaluation of molecular guided 
therapy for diffuse large B-cell lymphoma with 
bortezomib (REMoDL-B) study aimed to investigate the 
clinical efficacy of R-CHOP in addition to bortezomib 
in patients with diffuse large B-cell lymphoma. To 
determine whether the cell-of-origin subtypes respond 
differently to the combination of bortezomib with 
R-CHOP, we used a study design that incorporated 
prospective randomisation stratified by whole trans-
criptome gene-expression profiling. We also incor porated 
molecular characterisation into our analysis to assess 
recognised subgroups distinct from the cell-of-origin 
subgroups: double-hit (rearrangements of MYC and 
BCL2 or BCL6, or both) and double-expressor lymphomas 
(high expression of MYC and BCL2 proteins).
As clinical studies move towards increased application 
of targeted drugs against molecular phenotype, the 
feasibility of determining a molecular phenotype in 
real-time was an important objective of the study.
Methods
Study design and participants
In this multicentre, open-label, randomised, phase 3, 
superiority trial, we compared R-CHOP with R-CHOP 
plus bortezomib (RB-CHOP) in patients with newly 
diagnosed diffuse large B-cell lymphoma. In a collab-
oration between the UK National Cancer Research 
Institute group and the Schweiz Arbeitsgemeinschaft für 
Klinische Krebsforschung in Switzerland, patients were 
recruited from 107 cancer centres in the UK (n=94) and 
Switzerland (n=13). Patients were eligible for inclusion in 
the study if they had de novo diffuse large B-cell lymphoma 
confirmed by an expert haematopathologist (CB) with 
sufficient diagnostic material from previous biopsies for 
gene-expression profiling and central pathological review; 
were aged 18 years or older; had Eastern Cooperative 
Oncology Group (ECOG) performance status of 2 or less; 
had bulky stage I or stage II–IV disease requiring full-
course chemo therapy; had measurable disease; and had 
cardiac, lung, renal, and liver function sufficient to tolerate 
chemo therapy. Patients with a previous history of indolent 
lymphoma were excluded, but patients with previously 
undiagnosed concurrent low-grade infiltration in bone 
marrow or lymph nodes were eligible. Patients with 
primary mediastinal lymphoma; clinical CNS involve-
ment; positive serology for HIV, hepatitis B virus, or 
hepatitis C virus; active malignancy in the preceding 
5 years; or other conditions precluding administration of 
study treatment were ineligible. Pregnant women were 
also excluded. Full inclusion and exclusion criteria are in 
the appendix (pp 43–44).
The institutional review board at each study site 
approved the protocol. The full study protocol is available 
in the appendix (pp 15–90). Independent trial oversight 
was maintained by a trial steering committee and the 
data monitoring and ethics committee. The study was 
carried out according to the principles of the Declaration 
of Helsinki, Principles of the International Conference 
on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use Good 
Clinical Practice, and in accordance with UK and Swiss 
regulatory requirements. Written informed consent was 
obtained from all patients.
Randomisation and masking
Participants were centrally randomly assigned (1:1) with 
block randomisation of varying block size by TENALEA, a 
web-based system, to receive either R-CHOP (control) or 
RB-CHOP (experimental). Randomisation stratifi cation 
factors included cell-of-origin subtype and inter national 
prognostic index (IPI) score. For the purposes of stratifi-
cation, participants were grouped by their IPI scores as: 
low (0–1), intermediate (2–3), and high (4–5), and those 
with an unclassified cell-of-origin sub type were included. 
In cases of failed RNA extraction or insufficient RNA yield, 
participants were not randomly assigned but were given 
conventional R-CHOP treatment and followed up with the 
same assessments as participants in the control group, but 
analysed as a distinct group. Participants, investigators, 
and treating clinicians were unmasked to the treatment 
allocation; however, local investigators were not informed 
which molecular subgroup the participants were in.
Procedures
Participants underwent routine staging investigations, 
including CT scans and bone marrow biopsy, with 
examination of cerebrospinal fluid as clinically indicated. 
Tumour material was sent to the central laboratory 
(Haematological Malignancy Diagnostic Service, Leeds 
Cancer Cancer Centre, Leeds Teaching Hospitals, Leeds, 
UK) for gene-expression profiling and somatic mutation 
assessment.
For cycle one, all participants received the R-CHOP 
regimen on a 21-day schedule. The regimen comprised 
rituximab 375 mg/m² intravenously, cyclophosphamide 
750 mg/m² intravenously, doxorubicin 50 mg/m² intra-
venously, and vincristine 1·4 mg/m² (maximum total 
dose 2 mg) intravenously on day 1 of the cycle, and 
prednisolone 100 mg orally once daily on days 1–5. 
From cycle 2 onwards, participants were randomly 
assigned to their treatment groups, either to receive 
five further cycles of R-CHOP in the control group, or 
five cycles of R-CHOP plus bortezomib (RB-CHOP) on 
days 1 and 8 (1·3 mg/m² intravenously or 1·6 mg/m² 
See Online for appendix
For the TENALEA system see 
https://nl.tenalea.net/amc/
ALEA/Login.aspx
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subcutan eously) in the experimental group. Further 
cycles were given when neutrophils had recovered to 
1·0 × 10⁹ per L and platelets to 100 × 10⁹ per L; dose 
reductions of bortezomib in response to neurotoxicity 
were closely specified according to severity of this 
toxicity (appendix pp 48–53).
On Feb 28, 2014, we changed the route of bortezomib 
from intravenous to subcutaneous administration and 
updated the protocol after publication of data7 that 
suggested subcutaneous administration was associated 
with decreased toxicity and similar efficacy at a lower 
dose, and greater acceptability to patients, as compared 
with intravenous administration.8 Patients who were 
already being given intraveous bortezomib continued on 
this formulation. Allopurinol, granulocyte colony-
stimulating factor, and anti-emetic therapy were given 
according to local policy. Intrathecal prophylaxis with 
methotrexate was recommended for patients at high risk 
of CNS relapse for three to six cycles and could be given 
at any time at investigators’ discretion at each study site. 
Radiotherapy to initial bulky disease, extranodal sites, or 
residual masses was done according to routine practice 
in the participating centres. Cross-sectional imaging was 
repeated 1 month after administration of the final dose of 
chemotherapy to assess disease response using the 
International Working Group Response Criteria for non-
Hodgkin lymphoma9 and repeated at 12 months.
Participants were assessed clinically at the beginning 
of each treatment cycle and after treatment completion 
every 3 months for 1 year and thereafter every 6 months 
until 5 years’ total follow-up. At each assessment, medical 
history was recorded including adverse events, and 
patients underwent a physical examination, ECOG 
performance status assessment, and routine laboratory 
tests. Progressions were recorded after clinical assess-
ment and imaging, determined by local investigators, 
according to standard criteria,9 and at progression trial 
treatment was discontinued and patients were followed 
up until data cut off for survival.
Histological haematoxylin and eosin sections from 
formalin-fixed paraffin-embedded (FFPE) samples taken 
at diagnosis were reviewed in the central laboratory as a 
quality check. Macrodissection of tumours was done by 
scraping the area of interest from unstained sections on 
plain microscope slides. RNA was extracted using an 
Ambion RecoverAll Total Nucleic Acid Isolation Kit for 
FFPE (ThermoFisher, Waltham, MA, USA) according to 
the manufacturer’s protocol, with the exception that two 
washes in xylene and alcohol were used to remove wax, 
with extended digestion in proteinase K overnight.
During cycle 1 of R-CHOP, gene-expression profiling 
was done (by SB) using Illumina whole genome cDNA-
mediated annealing, selection, extension, and ligation 
(DASL) assay (Illumina, San Diego, CA, USA). Patient 
samples were classified as activated B-cell, germinal 
centre B-cell, unclassified, or fail (ie, insufficient quality 
or quantity of DNA or failure of DASL array) by use of 
the DASL automated classifier as previously described,10 
with a quality control of a score over 1 to define technical 
failure. The confidence of each sample being one of the 
three classes was recorded and the final classification 
was defined as that with the highest confidence score.
When possible, we used tissue from the biopsy sample 
to construct tissue micorarrays for immunohisto-
chemistry, fluorescence in-situ hybrid isation, and DNA 
extraction. Specifically, we did immunohistochemistry for 
MYC and BCL2 protein (dual) expression using these 
tissue micorarrays and Abcam rabbit monoclonal 
antibodies (Abcam, Cambridge, UK; clone Y69), with a 
cutoff of 40% or more, and Dako anti-BCL-2 monoclonal 
antibodies (Agilent, Santa Clara, USA; clone 124) with a 
cutoff of 50% or more, scored by two independent 
assessors according to recognised criteria. In the event of 
a disagreement about the score, a third assessor would 
arbitrate. For samples that could not be defined as positive 
or negative for expression of one of the proteins, these 
samples were defined as borderline. Using these criteria, 
samples with high or average MYC expresion and high or 
average BCL2 expression were used to define cutoff values 
for associated mRNA concentrations. These cutoff values 
were used to identify categories of MYC and BCL2 gene 
expression: high or average.
DNA was extracted from tumour cells enriched by 
microdissection on FFPE tissue sections and its quality 
was assessed by PCR of variously sized genomic frag-
ments. A panel of 70 genes that are recurrently mutated 
in aggressive B-cell lymphomas were investigated for 
mutation by targeted sequencing using HaloPlexHS target 
enrichment (Agilent Technologies, Santa Clara, CA, USA) 
and Illumina HiSeq sequencing, as described previously.11 
This process was carried out for participants who had 
DNA available of adequate quantity and quality. Duplicate 
experiments were done for samples of lower quality, 
including all those with quality control PCR showing 
amplification of 300 bp or fewer genomic fragments, and 
only those mutations that were repro ducible in both 
experiments were reported. Samples of better quality were 
investigated in a single replicate. Variant calling, single 
nucleotide polymorphisms, and back ground noise filter-
ing were done as previously described.11 In a further 
22 samples, mutations in 20 genes (included in the above 
panel of 70 genes) were analysed in duplicate using 
Fluidigm multiplex PCR (Fluidigm, South San Francisco, 
CA, USA) and Illumina MiSeq sequencing, as described 
previously, because of evolution of molecular diagnostics 
during the study period.11
Variants detected by use of these targeted sequencing 
methods were further assessed by use of functional 
prediction tools. These tools comprised SIFT, Polyphen2 
HDIV, Polyphen2 HVAR, LRT, MutationTaster, 
MutationAssessor, FATHMM, SVM score, and LR score, 
which predict whether or not a variant has an effect on 
the protein function, and those variants predicted to be 
benign by seven or more of nine programs, not in the 
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Catalogue Of Somatic Mutations In Cancer database, 
were excluded. The resulting variants were further 
scrutinised by reviewing the binary alignment map 
(.bam) file to eliminate any potential PCR or sequence 
artefacts. As part of a post-hoc analysis, samples were 
tested for the possible presence of primary mediastinal 
lymphoma using a Bayesian predictor described by the 
Lymphoma Molecular Profiling Project to ensure that no 
molecular cases of primary mediastinal lymphoma had 
been included.12
Safety was assessed by the recording and grading of 
adverse events according to the Common Terminology 
Criteria for Adverse Event Reporting Version 4.0 at each 
study visit, or between visits if notified. The assessment 
of causality was related to the study drugs by the local 
investigator. Serious or severe adverse events, including 
mention of suspected unexpected serious adverse 
reactions were defined as per the medicines for human 
use (clinical trials) regulations 2004.
Outcomes
The primary endpoint was 30-month progression-free 
survival in the germinal centre and activated B-cell 
popualtion, defined as time from registration to the date of 
progression or death from any cause. Disease progression 
was determined using the International Working Group 
Response Criteria for non-Hodgkin lymphoma.9 Partici-
pants free from progres sion or death were censored at the 
date of their last visit. Secondary outcomes were 30-month 
progression-free survival by cell-of-origin subgroup; the 
time-to-event variables of overall survival, event-free 
survival, disease-free survival, and time to progression; 
response duration; complete and overall proportion of 
patients who achieved a response; assessment of toxicity; 
quality of life; assess ment of peripheral neuropathy up to 
30 days after last treatment; and safety. The proportion of 
patients who achieved a complete and overall response, 
duration of response, event-free survival, disease-free 
survival, time-to-progression, and quality-of-life assess-
ments will be reported elsewhere. Exploratory analyses 
were planned for potential prognostic factors that emerged 
during the course of the trial, particularly new genomic 
risk categories. 
Statistical analysis
We used an adaptive design based on a two-stage 
approach, with two interim analyses to explore the safety 
and efficacy in the germinal centre B-cell group treated 
with RB-CHOP after a defined number of events. The 
first interim analysis was to take place once 55 patients in 
the germinal centre B-cell group had been randomly 
assigned to receive RB-CHOP. If progression-free 
survival at 12 months was assessed to be below 70% in 
this subgroup, the trial would stop recruiting into the 
germinal centre B-cell group. The second interim 
analysis was to take place when 73 patients in the 
germinal centre B-cell group had been randomly 
assigned to receive RB-CHOP and followed up for 1 year. 
If the progression-free survival at 12 months was assessed 
to be below 85% in this subgroup, the trial would stop 
recruiting into the germinal centre B-cell group.
The trial was powered to detect an improvement in 
progression-free survival at 30 months of 10% in the 
combined activated B-cell and germinal centre B-cell 
groups, from 75% in the R-CHOP group to 85% in the 
RB-CHOP group (corresponding to a hazard ratio 
[HR] of 0·56), on the basis of a log-rank test with a 
significance level of 5% (two-sided) and 90% power, 
requiring a total of 129 events. The intention-to-treat 
(ITT) population comprised all patients for whom gene-
expression profiling was attempted (classified as 
activated B-cell, germinal centre B-cell, or unclassified 
subgroups, or for whom gene-expression profiling 
failed). The safety population was formed of all patients 
in the ITT population who received at least one dose of 
any study drug.
We assessed the primary outcome of 30-month 
progression-free survival in a modified ITT (mITT) 
population comprising the activated and germinal centre 
B-cell subgroups who were randomly assigned to receive 
treatment, using a Cox proportional hazards model, 
adjusted for cell-of-origin subtype and IPI score.
Secondary outcome analyses included repeating the 
primary outcome analysis in the activated B-cell ITT 
population alone, the germinal centre B-cell ITT popu-
lation, and the unclassified ITT population, adjusting for 
IPI score only. We produced Kaplan-Meier curves for 
time-to-event data and we described follow-up maturity 
by the reverse Kaplan-Meier method. We used summary 
statistics to describe baseline chara cteristics for partici-
pants in the R-CHOP group, RB-CHOP group, and 
patients for whom gene-expression profiling had failed in 
the ITT population, and by cell-of-origin subgroups in the 
ITT population, with formal com parisons between cell-of-
origin subgroups using Pearson χ² tests. Toxicity infor-
mation was summarised by treatment group, and we did 
post-hoc analyses to compare toxicity information by 
treatment using Pearson χ² tests for the safety popu lation. 
Further post-hoc analyses included repeating the primary 
outcome analysis and adjusting for time from diagnosis 
to the start of treatment to ascertain whether or not 
the interval from diagnosis to treatment affected the 
progression-free survival outcome. We also did post-hoc 
analyses to assess progression-free survival and overall 
survival by treatment group in the mITT population in 
the IPI low, intermediate, and high score groups, assessed 
using a Cox proportional hazards model, adjusted for cell-
of-origin subtype, and also repeated the primary outcome 
analysis excluding patients who had a dose reduction in 
any treatment drug. We made no adjustment for multiple 
comparisons.
Post-hoc analyses to assess progression-free survival 
also included: comparing double-hit lymphomas to 
non-rearranged cases, separated by treatment group; 
For the medicines for human 
use (clinical trials regulations 
2004 see http://www.legislation.
gov.uk/uksi/2004/1031/made
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com paring double-expressor lymphomas to all other 
cases, separated by treatment group; and comparing by 
treat ment groups in subgroups with mutations in 
components of the NF-κB pathway.
We used Stata statistical software (version 15.1) for all 
analyses. This trial is registered with ClinicalTrials.gov, 
number NCT01324596.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had final responsibility for the decision 
to submit for publication.
Results
Between June 2, 2011, and June 10, 2015, of 3449 patients 
assessed for eligibility, 1128 (32·7%) participants were 
registered to the study (figure 1). Of the registered 
participants, a further 52 who received one cycle of 
R-CHOP were excluded for reasons including ineligibility 
after tumour biopsy (n=29) and insufficient tumour data 
Figure 1: Study profile
ITT=intention-to-treat. R-CHOP=rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. RB-CHOP=rituximab, bortezomib, cyclophosphamide, doxorubicin, vincristine, and 
prednisolone.
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(n=5). 158 (14·7%) of 1076 remaining participants had 
inadequate sample material for gene-expression profiling 
and so were excluded from subsequent random 
assignment to treatment, and instead given R-CHOP as 
per the control group. 918 (85·3%) of 1076 participants 
were stratified by cell-of-origin subtype and IPI and 
randomly assigned to receive R-CHOP or RB-CHOP 
(figure 1). Overall, 244 (26·6%) patients had activated 
B-cell disease, 475 (51·7%) had germinal centre B-cell 
disease, and 199 (21·7%) had unclassified disease. The 
planned interim analyses and safety assessments by the 
data monitoring and ethics committee in the germinal 
centre B-cell group showed the 1-year progression-free 
survival to be 70% or above in the germinal centre B-cell 
subgroup at the first interim analysis and the 1-year 
progression-free survival to be 85% or above in the 
germinal centre B-cell subgroup at the second interim 
analysis. Hence, the trial continued to recruit to all 
groups.
Baseline characteristics were similar between the 
control group, experimental group, and non-randomised 
participants (table 1). The median turnaround time from 
tumour samples reaching the diagnostic laboratory to a 
cell-of-origin result being available was 8 days (IQR 6–12). 
14·7% (158 of 1076) of samples failed, mainly because of 
insufficient tissue remaining in the block. For the 
samples from which sufficient material was extracted, 
only 1% (11 of 1076) failed for technical reasons.
We observed clinical differences between the molecular 
subgroups (table 2). Median age was higher in the 
activated B-cell subgroup (p=0·0045) and bulky disease 
occurred more often in the germinal centre B-cell 
subgroup (p<0·0001). Patients with bone marrow 
involve ment were over-represented in the unclassified 
subgroup. No significant difference was seen between 
the activated and germinal centre B-cell subgroups in 
the distribution of IPI risk group, serum lactate 
dehydrogenase (LDH) concentration above the upper 
limit of normal, conventional stage of disease, overall 
prevalence of extranodal disease, or ECOG performance 
status (table 2; appendix p 6). Post-hoc testing for the 
possible presence of primary mediastinal lymphoma 
identified 19 participants who fulfilled the criteria,12 of 
whom 13 (68%) had mediastinal disease. Of these 
participants, 14 (74%) had been allocated to the germinal 
centre B-cell group and five (26%) to the unclassified 
subgroup.
The primary efficacy outcome was analysed when the 
combined activated and germinal centre B-cell mITT 
population had been followed up for a median of 
30 months, as stipulated in the protocol (median 
follow-up 29·7 months [95% CI 29·0–32·0]; median 
follow-up of survivors: 29·4 months [28·6–31·1]). In the 
combined activated and germinal centre B-cell mITT 
population, 198 progression-free survival events (ie, 
progression or death) occurred (in 107 [29·6%] of 
361 participants in the R-CHOP group and in 91 [25·4%] 
of 358 in the RB-CHOP group), giving a Kaplan-Meier 
estimate of 30-month progression-free survival of 70·1% 
(95% CI 65·0–74·7) for the R-CHOP group and 74·3% 
(69·3–78·7) for the RB-CHOP group. We saw no 
difference in pro gression-free survival in the combined 
activated and germinal centre B-cell populations between 
the R-CHOP and RB-CHOP groups (HR 0·86, 95% CI, 
95% CI 0·65–1·13; p=0·28; adjusted HR 0·84, 95% CI 
0·64–1·11; p=0·23). 116 overall survival events (ie, deaths) 
occurred (62 in the R-CHOP group and 54 in the 
RB-CHOP group). The Kaplan-Meier estimate for 
30-month overall survival was 82·7% (95% CI 78·2–86·3) 
for the R-CHOP group and 83·6% (79·0–87·3) for the 
RB-CHOP group (HR 0·89, 95% CI 0·62–1·28; p=0·52; 
adjusted HR 0·85, 0·59–1·23; p=0·40). 
Although no adjustment for multiple testing was done, 
efficacy analyses were repeated after additional follow-up 
data were collected. After a median follow-up of survivors 
in the mITT population of 42·3 months (95% CI 
40·9–45·6), 211 progression-free survival events were 
observed (115 [31·9%] of 361 in the R-CHOP group and 
R-CHOP (n=459) RB-CHOP (n=459) Not randomised (n=158)
Age, years 65 (24–86) 63 (20–84) 65 (24–85)
ECOG performance status n=443 n=443 n=154
0 250 (56·4%) 222 (50·1%) 73 (47·4%)
1 142 (32·1%) 168 (37·9%) 57 (37·0%)
2 51 (11·5%) 53 (12·0%) 24 (15·6%)
Bone marrow involvement n=448 n=448 n=157
Yes 78 (17·4%) 63 (14·1%) 34 (21·7%)
No 370 (82·6%) 385 (85·9%) 123 (78·3%)
Serum LDH level n=377 n=368 n=108
>ULN 224 (59·4%) 227 (61·7%) 77 (71·3%)
≤ULN 153 (40·6%) 141 (38·3%) 31 (28·7%)
IPI score
Low (0–1) 123 (26·8%) 120 (26·1%) 33 (20·9%)
Low intermediate (2) 111 (24·2%) 123 (26·8%) 45 (28·5%)
High intermediate (3) 145 (31·6%) 133 (29·0%) 51 (32·3%)
High (4–5) 80 (17·4%) 83 (18·1%) 29 (18·4%)
Stage of disease n=457 n=457 n=157
I 12 (2·6%) 14 (3·1%) 5 (3·2%)
II 131 (28·7%) 126 (27·6%) 37 (23·6%)
III 128 (28·0%) 154 (33·7%) 48 (30·6%)
IV 186 (40·7%) 163 (35·7%) 67 (42·7%)
Bulk >10 cm n=456 n=450 n=149
Yes 122 (26·8%) 141 (31·3%) 66 (42·6%)
Molecular phenotype
Activated B cell 121 (26·4%) 123 (26·8%) ··
Germinal centre B cell 240 (52·3%) 235 (51·2%) ··
Unclassified 98 (21·4%) 101 (22·0%) ··
Data are median (range) or n (%). R-CHOP=rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. 
RB-CHOP=rituximab, bortezomib, cyclophosphamide, doxorubicin, vincristine, and prednisolone. ECOG=Eastern 
Cooperative Oncology Group. LDH=lactate dehydrogenase. ULN=upper limit of normal. IPI=international prognostic 
index.
Table 1: Baseline characteristics of the participants by treatment group
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96 [26·8%] of 358 in the RB-CHOP group), and 
133 overall survival events were observed (72 [19·9%] of 
361 participants died in the R-CHOP group and 
61 [17·0%] of 358 died in the RB-CHOP group). After this 
additional follow-up, the Kaplan-Meier estimate for 
30-month progression-free survival in the combined 
activated and germinal centre B-cell mITT population 
was 70·6% (95% CI 65·5–75·0) for the R-CHOP group 
and 75·2% (70·3–79·4) for the RB-CHOP group. We saw 
no evidence of difference in 30-month progression-free 
survival in the mITT population between the R-CHOP 
and RB-CHOP groups (adjusted HR 0·82, 95% CI 
0·63–1·08; p=0·16; figure 2A).
Secondary analysis of subtypes by cell of origin showed 
that bortezomib did not significantly affect progression-
free survival in either the activated B-cell (adjusted 
HR 0·78, 95% CI 0·51–1·21; p=0·27), germinal centre 
B-cell (0·85, 0·60–1·20; p=0·35), or unclassifiable 
participants (1·29, 95% CI 0·77–2·16; p=0·34; figure 2). 
We saw no difference in overall survival by treatment 
group in the mITT population (72 deaths in the R-CHOP 
group and 61 in the RB-CHOP group; adjusted HR 0·82, 
95% CI 0·59–1·16; p=0·27), and the Kaplan-Meier 
estimate of overall survival at 30 months was 81·6% 
(95% CI 77·1–85·3) in the R-CHOP group versus 83·1% 
(78·7–86·7) in the RB-CHOP group (appendix p 3).
The addition of bortezomib to R-CHOP was well 
tolerated (table 3). The most common grade 3 or worse 
adverse event was haematological toxicity, in 178 (39·8%) 
of 447 patients given R-CHOP and 187 (42·1%) of 444 given 
RB-CHOP. However, in a post-hoc analysis of adverse 
events between groups, we saw no significant increase in 
the proportion of patients who had grade 3 or worse 
neutropenia, febrile neutropenia, thrombo cytopenia, or 
anaemia. Neuropathy of any grade was more frequent in 
participants given RB-CHOP than among those given 
R-CHOP (252 (56·8%) RB-CHOP vs 186 (41·6%) given 
R-CHOP; p<0·0001; appendix pp 8–11) but there was no 
significant difference in the event rate of neuropathy of 
grade 3 or higher (17 (3·8%) RB-CHOP vs eight (1·8%) 
R-CHOP; p=0·070). 190 (42·5%) participants given 
R-CHOP versus 223 (50·2%) given RB-CHOP had serious 
adverse events. Nine suspected unexpected serious adverse 
reactions were reported: four reactions in four participants 
in the R-CHOP group (haemophagocytic syndrome, 
leukaemia secondary to chemotherapy, neutropenic sepsis, 
and fracture), and five reactions in four participants in the 
RB-CHOP group (jejunal stricture with small bowel 
obstruction, bowel perforation, sepsis, and one patient had 
both renal failure and tumour lysis syndrome). In the 
safety population, 73 (16·3%) of 447 participants in the 
R-CHOP group and 68 (15·3%) of 444 in the RB-CHOP 
group died, with most deaths due to progressive lymphoma 
(50 [68·5%] of 73 in the R-CHOP group, and 54 [79·4%] of 
68 in the RB-CHOP group); nine treatment-related deaths 
were reported (five [6·8%] of 73 in the R-CHOP group, 
four [5·9%] of 68 in the RB-CHOP group; appendix p 13).
In the ITT population, fewer participants in the R-CHOP 
group had dose reductions in any drug than did those in 
the RB-CHOP group (158 [34·5%] of 459 vs 196 [42·9%] of 
459, not including the non-randomsied participants; 
appendix p 12). Fewer participants discon tinued from trial 
treatments in the R-CHOP group than in the RB-CHOP 
group (43 [9·4%] vs 60 [13·1%]; appendix p 11). However, 
median relative dose intensity for participants in the 
control and experimental groups was similar for drugs 
comprising R-CHOP and a high proportion of participants 
in both groups success fully completed six cycles of treat-
ment: 418 (91·3%) of 459 in the R-CHOP group and 
398 (87·1%) of 459 in the RB-CHOP group (appendix p 12).
The median time from diagnosis to first treatment was 
similar between treatment groups (R-CHOP 17 days 
[IQR 10–29]; RB-CHOP 20 days [10–32]). Post-hoc 
analyses, repeating the primary analysis and adjusting 
for the time from diagnosis to first treatment interval 
also showed no difference in 30-month progression-free 
survival in the mITT population between the R-CHOP 
and RB-CHOP groups (70·6%, 95% CI 65·5–75·0 for 
R-CHOP, and 75·2%, 70·3–79·4 for RB-CHOP; adjusted 
HR 0·83, 95% CI 0·56–1·24; p=0·36). Similarly, post-hoc 
analyses excluding patients who had a dose reduction in 
any treatment drug showed no difference in 30-month 
progression-free survival in the mITT population 
between the R-CHOP and RB-CHOP groups (68·9%, 
95% CI 62·4–74·5 for R-CHOP and 74·3%, 65·8–81·0 
for RB-CHOP; adjusted HR 0·80, 95% CI 0·54–1·19; 
Activated B-cell 
subgroup 
(n=244)
Germinal centre 
B-cell subgroup 
(n=475)
Unclassified 
subgroup 
(n=199)
p value 
(activated vs 
germinal 
centre B-cell 
groups)
Age, years 67 (22–86) 63 (20–82) 63 (20–84) 0·0045
ECOG performance status n=233 n=459 n=194 0·83
0 121 (51·9%) 247 (53·8%) 104 (53·6%) ··
1 84 (36·1%) 158 (34·4%) 68 (35·1%) ··
2 28 (12·0%) 54 (11·8%) 22 (11·3%) ··
Bone marrow involvement 33/240 (13·8%) 66/465 (14·2%) 42/191 (22·0%) 0·017
Serum LDH level >ULN 115/189 (60·8%) 231/386 (59·8%) 105/170 (61·8%) 0·19
IPI score n=244 n=475 n=199 0·822
Low (0–1) 66 (27·0%) 127 (26·7%) 50 (25·1%) ··
Low intermediate (2) 70 (28·7%) 117 (24·6%) 47 (23·6%) ··
High intermediate (3) 69 (28·3%) 144 (30·3%) 65 (32·7%) ··
High (4–5) 39 (16·0%) 87 (18·3%) 37 (18·6%) ··
Stage of disease n=244 n=471 n=199 0·74
I 8 (3·3%) 12 (2·5%) 6 (3·0%) ··
II 76 (31·1%) 134 (28·5%) 47 (23·6%) ··
III 73 (29·9%) 148 (31·4%) 61 (30·7%) ··
IV 87 (35·7%) 177 (37·6%) 85 (42·7%) ··
Bulk >10 cm 50/241 (20·7%) 158/467 (33·8%) 55/198 (27·8%) <0·0001
Data are median (range), n (%), or n/N (%). ECOG=European Cooperative Oncology Group. LDH=lactate 
dehydrogenase. ULN=upper limit of normal. IPI=international prognostic index.
Table 2: Clinical characteristics of participants in intention-to-treat population by cell-of-origin subtypes
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p=0·27). Post-hoc analysis of progression-free survival 
and overall survival by IPI score are shown in the 
appendix (p 4).
The panel of genomic mutations confirmed the known 
association of different somatic changes with cell-of-
origin subtypes, with a bias towards alterations in 
epigenetic modifier genes in the germinal centre B-cell 
subgroup and genes of the B-cell receptor signalling 
pathway in the activated B-cell subgroup (appendix 
pp 2, 6, 7). Mutations in EZH2 were seen in 25·0% (53 of 
212) of germinal centre B-cell biopsy samples but only 
4·2% (five of 118) of activated B-cell samples, and 
conversely mutations in MYD88 were found in 9·0% 
(19 of 212) of germinal centre B-cell and 44·9% (52 or 
118) of activated B-cell samples tested (appendix pp 1, 6, 7). 
NF-κB target genes were expressed at higher levels in the 
activated B-cell subgroup compared with the germinal 
centre B-cell group (appendix p 2).
417 biopsy samples (118 from the activated B-cell 
subgroup, 212 from the germinal centre B-cell subgroup, 
and 87 from the unclassified subgroup) were suitable 
for construction of tissue microarrays. We analysed 
recognised prognostic subgroups in the ITT population 
(appendix p 13). Karyotypic double-hit lymphomas were 
rare in the activated B-cell population and were 
significantly associated with the germinal centre B-cell 
subtype (one [0·4%] of 244 vs 32 [6·7%] of 475; p<0·0001). 
Conversely, the activated B-cell subtype was associated 
with higher concomitant expression of MYC and BCL-2 
proteins (ie, double-expressor lymphomas) than the 
germinal centre B-cell subtype was by immuno histo-
chemistry analysis (excluding double-hit lymphomas; 
56 [54·9%] vs 45 [26%]; p<0·0001) and mRNA (109 
[44·7%] vs 87 [18·3%]; p<0·0001; appendix p 13).
395 biopsy samples had sufficient DNA of adequate 
quantity and quality for investigation of mutations via 
targeted sequencing. 61 samples had to undergo a 
duplicate analysis because they were not of sufficient 
quality, and in 22 samples, mutations in 20 genes were 
further analysed. Among the participants given R-CHOP 
(including the non-randomised group), MYC rearrange-
ment, double-hit lymphoma, and dual high MYC and 
BCL-2 mRNA expression were significantly associated 
with inferior progression-free survival after controlling 
for IPI (data not shown). Participants in the R-CHOP 
group with either double-hit lymphoma (n=18) or dual 
high expression of MYC and BCL-2 mRNA (ie, double-
expressor lymphoma; n=102) had signifi cantly worse 
progression-free survival at 30 months than participants 
Figure 2: Progression-free survival in the m ITT population (A), activated 
B-cell subgroup (B), germinal centre B-cell subgroup (C), and unclassified 
group (D), by treatment
Data are for the mITT population, which comprises germinal centre and 
activated B-cell ITT participants (n=719); activated B-cell subgroup (n=244); 
germinal centre B-cell subgroup (n=475); and unclassified subgroup (n=199); 
with estimated proportions of participants achieving progression-free survival 
at 12 months and 30 months. HR=hazard ratio. ITT=intention-to-treat. 
mITT=modified ITT. R-CHOP=rituximab, cyclophosphamide, doxorubicin, 
vincristine, and prednisolone. RB-CHOP=rituximab, bortezomib, 
cyclophosphamide, doxorubicin, vincristine, and prednisolone.
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in the same treatment group without these rearrange-
ments (double-hit lymphoma in the R-CHOP group: 
38·9% vs 75·8%, adjusted HR 3·07, 95% CI 1·64–5·76; 
p=0·00048; and dual-expressor lymphoma in the 
R-CHOP group: 61·5% vs 75·8%, adjusted HR 1·81, 
1·26–2·60; p=0·0013; figure 3). High con centrations of 
MYC and BCL-2 proteins by immunohistochemistry did 
not appear to have a significant effect on outcomes, 
although few participants had high concentrations of 
these proteins, resulting in wide confidence limits 
(figure 4). The effect of bortezomib on progression-free 
survival in these high-risk groups is shown in figure 4.
We examined the effect of the addition of bortezomib 
on survival in patients with mutations known to be 
associated with activation of NF-κB, the putative target 
of bortezomib (MYD88, CD79A, CD79B, TNFAIP3, 
TNFRSF11A) and found no significant differences for 
single gene alterations (appendix p 5).
Discussion
In this trial, we have shown the feasibility of molecular 
phenotyping in a large multicentre study of rapidly 
progressive tumours and shown that the addition of 
bortezomib does not affect treatment outcomes in most 
patients with diffuse large B-cell lymphoma. Because 
patients entering clinical trials are often not representative 
of the wider population, for prospective testing of a 
complex biomarker we wished to avoid worsening the 
problem of generalisability by restricted enrolment and 
delays to the initiation of therapy. Such delays were 
avoided by studying routine FFPE biopsy samples and 
deferring random assignment to a treatment group until 
the second cycle of R-CHOP, thereby allowing treatment 
to start as soon as staging investigations were completed, 
with molecular analysis taking place in parallel. Deferred 
introduction of the experimental drug had a further 
advantage, because more treatment-related deaths 
(around 62%) in diffuse large B-cell lymphoma treatment 
cycles are reported after the first cycle than at any other 
timepoint,13 a proportion that might increase with an 
additional drug.
To our knowledge, all previous studies of gene-
expression profiling in lymphoma have been retro-
spective; assignment of patients to novel therapies on the 
R-CHOP (n=447) RB-CHOP (n=444)
Grade 1–2 Grade 3 Grade 4 Grade 5 Grade 1–2 Grade 3 Grade 4 Grade 5
Any adverse event 414 (92·6%) 226 (50·6%) 107 (23·9%) 6 (1·3%) 415 (93·5%) 253 (57·0%) 105 (23·6%) 4 (0·9%)
Haematological 115 (25·7%) 128 (28·6%) 96 (21·5%) 1 (0·2%) 118 (26·6%) 153 (34·5%) 89 (20·0%) 1 (0·2%)
Neutropenia 51 (11·4%) 107 (23·9%) 92 (20·6%) 1 (0·2%) 62 (14·0%) 137 (30·9%) 81 (18·2%) 1 (0·2%)
Thrombocytopenia 22 (4·9%) 5 (1·1%) 2 (0·4%) 0 36 (8·1%) 7 (1·6%) 7 (1·6%) 0
Anaemia 73 (16·3%) 19 (4·3%) 0 0 82 (18·5%) 14 (3·2%) 0 0
Neuropathy 183 (40·9%) 8 (1·8%) 0 0 249 (56·1%) 17 (3·8%) 0 0
Nausea or vomiting 160 (35·8%) 7 (1·6%) 0 0 194 (43·7%) 15 (3·4%) 1 (0·2%) 0
Febrile neutropenia 8 (1·8%) 49 (11·0%) 14 (3·1%) 0 7 (1·6%) 51 (11·5%) 9 (2·0%) 0
Neutropenic sepsis 3 (0·7%) 9 (2·0%) 23 (5·1%) 1 (0·2%) 3 (0·7%) 19 (4·3%) 11 (2·5%) 1 (0·2%)
Febrile neutropenia 
or neutropenic sepsis
11 (2·5%) 55 (12·3%) 33 (7·4%) 1 (0·2%) 10 (2·3%) 67 (15·1%) 20 (4·5%) 1 (0·2%)
Abdominal pain 61 (13·6%) 12 (2·7%) 1 (0·2%) 0 64 (14·4%) 9 (2·0%) 0 0
Alopecia 114 (25·5%) 9 (2·0%) 0 0 106 (23·9%) 6 (1·4%) 0 0
Constipation 165 (36·9%) 1 (0·2%) 0 0 180 (40·5%) 5 (1·1%) 0 0
Cough 53 (11·9%) 0 0 0 63 (14·2%) 1 (0·2%) 0 0
Diarrhoea 95 (21·3%) 10 (2·2%) 0 0 133 (30·0%) 24 (5·4%) 0 0
Dyspnoea 56 (12·5%) 4 (0·9%) 0 0 59 (13·3%) 4 (0·9%) 0 0
Fatigue 201 (45·0%) 10 (2·2%) 0 0 191 (43·0%) 8 (1·8%) 0 0
Fever 64 (14·3%) 17 (3·8%) 1 (0·2%) 0 87 (19·6%) 14 (3·2%) 1 (0·2%) 0
Mucositis 73 (16·3%) 2 (0·4%) 0 0 62 (14·0%) 6 (1·4%) 0 0
Nausea 141 (31·5%) 3 (0·7%) 0 0 165 (37·2%) 8 (1·8%) 1 (0·2%) 0
Pain 56 (12·5%) 5 (1·1%) 0 0 69 (15·5%) 6 (1·4%) 0 0
Peripheral sensory 
neuropathy
129 (28·9%) 3 (0·7%) 0 0 182 (41·0%) 8 (1·8%) 0 0
Sepsis 2 (0·4%) 2 (0·4%) 12 (2·7%) 0 0 2 (0·5%) 15 (3·4%) 0
Vomiting 63 (14·1%) 6 (1·3%) 0 0 109 (24·5%) 11 (2·5%) 0 0
Data are for adverse events for which grade 1 or 2 events were reported in 10% or more of patients, adverse events for which grade 3, 4, or 5 events were reported in 2% or 
more of patients, and any other haematological or neutropenia-related adverse events reported. R-CHOP=rituximab, cyclophosphamide, doxorubicin, vincristine, and 
prednisolone. RB-CHOP=rituximab, bortezomib, cyclophosphamide, doxorubicin, vincristine, and prednisolone.
Table 3: Adverse events in the safety population
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basis of their molecular phenotype will require real-time 
outputs, which we have shown to be feasible in this trial. 
Using a central laboratory and the DASL automated 
classifier, we prospectively assigned cell-of-origin 
categories within a clinically relevant timeframe, which 
allowed random assignment to treatment to be stratified 
by cell-of-origin subtype, with the potential for adaptive 
design based on interim analyses of molecular subtypes. 
The accuracy of the classifier is supported by our 
identification of expected frequencies of different 
mutations that are known to be enriched in activated 
B-cell or germinal centre B-cell subtypes of disease.14 We 
identified that NF-κB target genes were more highly 
expressed in the activated B-cell subtype whereas almost 
all participants with double-hit lymphoma were identified 
within the germinal centre B-cell subgroup, which is 
Figure 3: Progression-free survival comparing double-hit lymphomas to non-rearranged cases (A) and double-expressor (high MYC and high BCL-2 mRNA) 
lymphomas to all other cases (B), by treatment group
Data are progression-free survival and hazard ratio (HR), with non-DHL and non-DEL patients as reference categories. DEL=dual-expressor lymphoma. 
DHL=double-hit lymphoma. R-CHOP=rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. RB-CHOP=rituximab, bortezomib, 
cyclophosphamide, doxorubicin, vincristine, and prednisolone.
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consistent with the published literature.15 Dual expression 
of MYC and BCL-2 proteins or mRNA was more frequent 
in participants with the activated B-cell subtype than in 
those with the germinal centre B-cell subgroup, and at 
similar frequencies to those previously reported.16
The overall frequency of the activated B-cell subtype 
(27%) was lower than has been reported in some 
retrospective studies, in which approximately equal 
numbers of patients with germinal centre B-cell and 
activated B-cell lymphoma were seen.15,17 However, a large 
randomised trial18 has reported very similar findings to 
our study, showing 58% of participants had germinal 
centre B-cell subtype, 26% activated B-cell, and 16% 
unclassifiable disease, by use of NanoString Lymphoma 
Subtyping Test.18 Some patients with lymphoma with 
poor prognostic features at presentation might be 
excluded from such trials on the grounds of performance 
status or the need for urgent treatment before screening 
procedures can be completed, which might reduce the 
proportion of patients with activated B-cell subtype 
disease entering prospective studies.
Our overall outcomes are consistent with those of other 
large prospective studies in diffuse large B-cell 
lymphoma, with similar progression-free survival (70·6% 
to 75·2% at 30 months) to other phase 3 trials.2,18 The 
progression-free survival for the ITT population was not 
improved by the addition of bortezomib at the doses used 
in this study, and neither was a differential effect of 
treatment seen according to the cell of origin. This 
observation is in keeping with the findings of a smaller 
randomised phase 2 study, in which the addition of 
bortezomib 1·3 mg/m² to R-CHOP on days 1 and 4 did 
not improve outcomes for non-germinal centre B-cell 
diffuse large B-cell lymphoma, defined in that study by 
immuno histochemistry.19
Administration of R-CHOP was not substantially 
compromised by the addition of bortezomib. Individual 
R-CHOP components had similar median relative dose 
intensities between groups and almost 90% of patients 
completed six cycles of treatment. The slight increase in 
neurotoxicity observed in participants in the RB-CHOP 
group compared with the R-CHOP group suggests that 
the bortezomib was given at a biologically active dose. 
Bortezomib was administered on days 1 and 8 of 
cycles 2–5, at a dose that has shown efficacy in other 
lymphoma trials,19,20 but we recognise that more potent 
proteasome inhibitors are now in use, as are other agents 
with apparent preferential effects in the activated B-cell 
subgroup, such as lenalidomide and ibrutinib, trials of 
which are in pro gress (NCT02285062, NCT01855750).
Bortezomib did not improve outcomes for participants 
with the activated B-cell subtype of diffuse large B-cell 
lymphoma, which was confirmed to be enriched for 
expression of NF-κB target genes, or for patients with 
somatic mutations associated with NF-κB activation. 
Inhibition of NF-κB might be insufficient to improve 
outcomes in addition to R-CHOP in diffuse large B-cell 
lymphoma, or bortezomib at the doses given might not 
have been sufficient to inhibit NF-κB adequately for 
outcomes to improve. Another study in patients with 
non-germinal centre B-cell lymphoma, selected by 
immunohistochemistry, did not show a difference 
between R-CHOP and the combination of rituximab, 
cyclophosphamide, doxorubicin, and prednisone (R-CHP) 
with bortezomib given in place of vincristine, supporting 
our finding.20
Studies18–20 have shown the difficulty of improving the 
results of initial therapy in diffuse large B-cell lymphoma 
by the addition of novel drugs that had promising activity 
in studies treating recurrent disease with a single 
Figure 4: Forest plot of hazard ratios based on progression free survival for participants at high risk and with different molecular subtypes of disease, 
by treatment group
Data are for all randomised participants (ie, ITT population). Hazard ratios and p values are effect estimates from a multivariable model adjusted for IPI score. 
DEL=dual-expressor lymphoma. DHL=double-hit lymphoma. IPI=inter national prognostic index. ITT=intention-to-treat. R-CHOP=rituximab, cyclophosphamide, 
doxorubicin, vincristine, and prednisolone. RB-CHOP=rituximab, bortezomib, cyclophosphamide, doxorubicin, vincristine, and prednisolone.
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treatment group. This situation might partly reflect 
biological selection through treatment failure: in relapsed 
or refractory lymphomas for which new drugs are 
investigated, the biology of such disease is likely to be 
different from that of newly diagnosed lymphomas. 
Thus, most germinal centre B-cell diffuse large B-cell 
lymphoma can be cured by R-CHOP, whereas recurrent 
disease is more common for those with double-hit 
lymphoma. Similarly, recurrent activated B-cell diffuse 
large B-cell lymphoma is enriched for double-expressor 
lymphomas, which might account for the different 
results reported in our study compared with the previous 
studies of bortezomib treatment. This observation 
highlights the need for full molecular char acterisation of 
the disease being treated, both at diagnosis and in the 
event of initial treatment failure.
In this study, the presence of a small number of 
participants with double-hit lymphoma in the germinal 
centre B-cell subgroup lowered the progression-free 
survival estimate for this subgroup. Overall, however, the 
progression-free survival outcome for the patients with 
double-hit lymphoma appears to be better than that 
reported in some earlier studies21 and is consistent with 
more recent analyses.22,23 Although clearly worse than 
the non-rearranged group, nearly half of double-hit 
lymphomas appeared to have not progressed at 
30 months. The progression-free survival at 30 months 
in patients with double-hit lymphoma was 38·9% after 
R-CHOP compared with 58·8% after RB-CHOP, 
although this result was from a post-hoc analysis and was 
not statistically significant (data not shown).
This study had several limitations. Any clinical trial is 
potentially prone to selective recruitment of those 
patients with better prognoses, but we endeavoured to 
minimise this effect by deferring random assignment to 
treatment until the second cycle of therapy, thereby 
allowing rapid initiation of treatment at the same time as 
molecular typing. As a result, the median time from 
diagnosis to initiation of therapy was lower than in 
similar studies,24 and the distribution of IPI scores in this 
study was similar to or worse than recent trials,2,18 with 
47% of patients being high-intermediate or high risk. 
Despite this limitation, the exclusion of patients with 
ECOG performance status of 3 or higher might have 
removed a cohort with the most adverse biology. We were 
unable to do a comprehensive central histopathology 
review on the participants enrolled and we did not assess 
for the presence of Epstein-Barr virus in the biopsy 
samples. However, all participants were diagnosed by 
expert haemato pathologists by use of a procedure with 
high accuracy for diffuse large B-cell lymphoma (over 
96% in a recent case series from the UK25), and because 
Epstein-Barr virus is present in less than 3% of diffuse 
large B-cell lymphoma in Europe,26 the presence of the 
virus would be unlikely to affect our results. The dose of 
bortezomib was chosen to reduce the risk of additive 
neurotoxicity, but as a result the dose might have been 
insufficient. The RB-CHOP group had a slight excess of 
vincristine dose reductions compared with the R-CHOP 
group, which could potentially have eroded a positive 
effect from the bortezomib. The use of routine FFPE 
biopsy samples was necessitated by the large number of 
recruiting centres, but resulted in a failure rate of about 
15% for molecular typing and might have resulted in a 
larger than expected number of unclassified cases for 
whom poor quality RNA resulted in a low probability 
score in the cell-of-origin classifier.
In conclusion, this trial has shown that complex 
molecular characterisation can be done in real time, with a 
pragmatic treatment schedule that allows for the allocation 
of therapy on the basis of the molecular subtype. This 
method is likely to become increasingly relevant as our 
understanding of the phenotypic diversity of diffuse large 
B-cell lymphoma expands to encompass not only cell of 
origin, but also other biologically distinct categories based 
on genomic alterations.15,27,28 Future trials that use such 
methods will be important to explore the mechanisms of 
action of investigational drugs and to redefine the groups 
in which they are most likely to be effective. The poor 
prognosis of double-hit lymphomas could be seen as a 
potential opportunity for such an approach.
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